199 related articles for article (PubMed ID: 21295472)
41. Structurally diverse 5-substituted pyrimidine nucleosides as inhibitors of Leishmania donovani promastigotes in vitro.
Torrence PF; Fan X; Zhang X; Loiseau PM
Bioorg Med Chem Lett; 2006 Oct; 16(19):5047-51. PubMed ID: 16879965
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis and antileishmanial in vitro activity of new series of chalcones-like compounds: a molecular hybridization approach.
Barbosa TP; Sousa SC; Amorim FM; Rodrigues YK; de Assis PA; Caldas JP; Oliveira MR; Vasconcellos ML
Bioorg Med Chem; 2011 Jul; 19(14):4250-6. PubMed ID: 21684751
[TBL] [Abstract][Full Text] [Related]
43. The antileishmanial properties of surface-modified, primaquine-loaded nanocapsules tested against intramacrophagic Leishmania donovani amastigotes in vitro.
Heurtault B; Legrand P; Mosqueira V; Devissaguet JP; Barratt G; Bories C
Ann Trop Med Parasitol; 2001 Jul; 95(5):529-33. PubMed ID: 11487374
[No Abstract] [Full Text] [Related]
44. Arylthiosemicarbazones as antileishmanial agents.
Manzano JI; Cochet F; Boucherle B; Gómez-Pérez V; Boumendjel A; Gamarro F; Peuchmaur M
Eur J Med Chem; 2016 Nov; 123():161-170. PubMed ID: 27475107
[TBL] [Abstract][Full Text] [Related]
45. Effect of pyrazoloquinoline derivatives on the growth of Leishmania donovani promastigotes.
Al-Qahtani A; Siddiqui YM; Bekhit AA; El-Sayed OA; Aboul-Enein HY; Al-Ahdalb MN
Arch Pharm (Weinheim); 2005 Oct; 338(10):484-7. PubMed ID: 16211660
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and biological evaluation of ferrocenylquinoline as a potential antileishmanial agent.
Yousuf M; Mukherjee D; Pal A; Dey S; Mandal S; Pal C; Adhikari S
ChemMedChem; 2015 Mar; 10(3):546-54. PubMed ID: 25619822
[TBL] [Abstract][Full Text] [Related]
47. In pursuit of natural product leads: synthesis and biological evaluation of 2-[3-hydroxy-2-[(3-hydroxypyridine-2-carbonyl)amino]phenyl]benzoxazole-4-carboxylic acid (A-33853) and its analogues: discovery of N-(2-benzoxazol-2-ylphenyl)benzamides as novel antileishmanial chemotypes.
Tipparaju SK; Joyasawal S; Pieroni M; Kaiser M; Brun R; Kozikowski AP
J Med Chem; 2008 Dec; 51(23):7344-7. PubMed ID: 18989953
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis and in vitro antiprotozoal activity of benzimidazole-pentamidine hybrids.
Torres-Gómez H; Hernández-Núñez E; León-Rivera I; Guerrero-Alvarez J; Cedillo-Rivera R; Moo-Puc R; Argotte-Ramos R; Rodríguez-Gutiérrez Mdel C; Chan-Bacab MJ; Navarrete-Vázquez G
Bioorg Med Chem Lett; 2008 Jun; 18(11):3147-51. PubMed ID: 18486471
[TBL] [Abstract][Full Text] [Related]
49. S-Euglobals: biomimetic synthesis, antileishmanial, antimalarial, and antimicrobial activities.
Bharate SB; Khan SI; Tekwani BL; Jacob M; Khan IA; Singh IP
Bioorg Med Chem; 2008 Feb; 16(3):1328-36. PubMed ID: 17976995
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and evaluation of novel triazolyl quinoline derivatives as potential antileishmanial agents.
Upadhyay A; Kushwaha P; Gupta S; Dodda RP; Ramalingam K; Kant R; Goyal N; Sashidhara KV
Eur J Med Chem; 2018 Jun; 154():172-181. PubMed ID: 29793211
[TBL] [Abstract][Full Text] [Related]
51. Redox-active dinitrodiphenylthioethers against Leishmania: synthesis, structure-activity relationships and mechanism of action studies.
Delfín DA; Morgan RE; Zhu X; Werbovetz KA
Bioorg Med Chem; 2009 Jan; 17(2):820-9. PubMed ID: 19058972
[TBL] [Abstract][Full Text] [Related]
52. Synthesis, antileishmanial activity and docking study of N'-substitutedbenzylidene-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetohydrazides.
Sangshetti JN; Shaikh RI; Khan FA; Patil RH; Marathe SD; Gade WN; Shinde DB
Bioorg Med Chem Lett; 2014 Mar; 24(6):1605-10. PubMed ID: 24513045
[TBL] [Abstract][Full Text] [Related]
53. Structure-activity relationship investigations of leishmanicidal N-benzylcytisine derivatives.
Turabekova MA; Vinogradova VI; Werbovetz KA; Capers J; Rasulev BF; Levkovich MG; Rakhimov SB; Abdullaev ND
Chem Biol Drug Des; 2011 Jul; 78(1):183-9. PubMed ID: 21457471
[TBL] [Abstract][Full Text] [Related]
54. Identification of the benzodiazepines as a new class of antileishmanial agent.
Clark RL; Carter KC; Mullen AB; Coxon GD; Owusu-Dapaah G; McFarlane E; Duong Thi MD; Grant MH; Tettey JN; Mackay SP
Bioorg Med Chem Lett; 2007 Feb; 17(3):624-7. PubMed ID: 17113290
[TBL] [Abstract][Full Text] [Related]
55. Discovery of 3,3'-diindolylmethanes as potent antileishmanial agents.
Bharate SB; Bharate JB; Khan SI; Tekwani BL; Jacob MR; Mudududdla R; Yadav RR; Singh B; Sharma PR; Maity S; Singh B; Khan IA; Vishwakarma RA
Eur J Med Chem; 2013 May; 63():435-43. PubMed ID: 23517732
[TBL] [Abstract][Full Text] [Related]
56. Original quinazoline derivatives displaying antiplasmodial properties.
Kabri Y; Azas N; Dumètre A; Hutter S; Laget M; Verhaeghe P; Gellis A; Vanelle P
Eur J Med Chem; 2010 Feb; 45(2):616-22. PubMed ID: 19926173
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and anti-leishmanial activity of novel symmetrical bispyridinium cyclophanes.
Gómez-Pérez V; Manzano JI; García-Hernández R; Castanys S; Gamarro F; Campos JM
Eur J Med Chem; 2015 Jan; 89():362-9. PubMed ID: 25462252
[TBL] [Abstract][Full Text] [Related]
58. Antiprotozoal and antimicrobial activities of O-alkylated and formylated acylphloroglucinols.
Bharate SB; Khan SI; Yunus NA; Chauthe SK; Jacob MR; Tekwani BL; Khan IA; Singh IP
Bioorg Med Chem; 2007 Jan; 15(1):87-96. PubMed ID: 17070063
[TBL] [Abstract][Full Text] [Related]
59. Azaterphenyl diamidines as antileishmanial agents.
Hu L; Arafa RK; Ismail MA; Wenzler T; Brun R; Munde M; Wilson WD; Nzimiro S; Samyesudhas S; Werbovetz KA; Boykin DW
Bioorg Med Chem Lett; 2008 Jan; 18(1):247-51. PubMed ID: 18006310
[TBL] [Abstract][Full Text] [Related]
60. Chemotherapy of leishmaniasis. Part XI: synthesis and bioevaluation of novel isoxazole containing heteroretinoid and its amide derivatives.
Suryawanshi SN; Tiwari A; Chandra N; Ramesh ; Gupta S
Bioorg Med Chem Lett; 2012 Nov; 22(21):6559-62. PubMed ID: 23031597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
